Literature DB >> 11716039

Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy.

S C Jyonouchi1, R W Valyasevi, D A Harteneck, C M Dutton, R S Bahn.   

Abstract

The thyrotropin receptor (TSHR) is the thyroid autoantigen against which stimulating autoantibodies are directed in Graves' hyperthyroidism. Recent evidence suggests that TSHR may also serve as an orbital autoantigen in Graves' ophthalmopathy (GO) and that expression of this protein is increased in the fatty connective tissues of the orbit in this condition. It has been shown that orbital fibroblasts from patients with GO increase thyrotropin (TSH)-dependent cyclic adenosine monophosphate (cAMP) production and TSHR gene expression when cultured under conditions known to stimulate adipocyte differentiation. In the current study, we wanted to determine whether treatment of these cells with particular cytokines (each 1 ng/mL) during differentiation might further augment TSHR expression. We found that exposure to interleukin (IL)-6 increased TSHR expression above control levels in cells from patients with GO. In contrast, this cytokine did not affect TSHR expression in normal orbital cells. Neither IL-4 nor IL-1alpha had a significant stimulatory effect in either normal or Graves' cultures. These findings suggest that IL-6 may play a role in the pathogenesis of GO by increasing expression of the putative autoantigen within the adipose/connective tissues of the orbit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716039     DOI: 10.1089/105072501753210984

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  19 in total

Review 1.  New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

Authors:  R A Ajjan; A P Weetman
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 2.  Insights into the role of fibroblasts in human autoimmune diseases.

Authors:  T J Smith
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

3.  Sphingosine-1-phosphate is involved in inflammatory reactions in patients with Graves' orbitopathy.

Authors:  Yuri Seo; Min Kyung Chae; Sol Ah Han; Eun Jig Lee; Joon H Lee; Jin Sook Yoon
Journal:  Inflamm Res       Date:  2017-03-31       Impact factor: 4.575

4.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

5.  Increased CD40+ Fibrocytes in Patients With Idiopathic Orbital Inflammation.

Authors:  Brian J Lee; Stephen Atkins; Anna Ginter; Victor M Elner; Christine C Nelson; Raymond S Douglas
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 May-Jun       Impact factor: 1.746

Review 6.  Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment.

Authors:  Sita Virakul; Leendert van Steensel; Virgil A S H Dalm; Dion Paridaens; P Martin van Hagen; Willem A Dik
Journal:  Eur Thyroid J       Date:  2014-12-06

Review 7.  TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy.

Authors:  R S Bahn
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

8.  Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.

Authors:  Alan Chun Hong Lee; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-08-10

9.  Graves' ophthalmopathy: a review of immunogenetics.

Authors:  Omid Khalilzadeh; Sina Noshad; Armin Rashidi; Aliakbar Amirzargar
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

10.  Tocilizumab for thyroid eye disease.

Authors:  Shirin Hamed Azzam; Swan Kang; Mario Salvi; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.